Esophagus Cancer
Conditions
Brief summary
It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.
Interventions
None listed
Sponsors
First Affiliated Hospital of Shantou University Medical College
Peking University Shenzhen Hospital
Guangdong Provincial People's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 78 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically diagnosed as esophageal squamous cell carcinoma * KPS≥80 * Adequate organ function * No distant metastasis * The diseases could be resected or potentially resectable after immunochemotherapy assessed by a thoracic oncologist
Exclusion criteria
* incomplete medical record which affects statistical analysis * have participated in previous interventional clinical trials * other situations evaluated by investigators not meet the enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | from the date of diagnosis to the date of death, assessed up to 100 months | Overall survival rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic complete response rate (pCR) | Three to five working days after surgery | The rate of pathologic complete response rate after the combined treatment of chemotherapy and immunotherapy following surgery |
Countries
China
Outcome results
None listed